Finch Therapeutics Q4 net loss $27M, cash $71M; patent litigation progress, PRISM4 discontinued

Finch Therapeutics Group, Inc.

Net loss Q4 $27.0M vs $19.1M in Q4 2021; FY2022 net loss $114.6M vs $58.2M in prior year.
Cash and equivalents $71.0M at Dec 31, 2022; estimated $43.3M at Feb 28, 2023; cash runway extended into 2025.
Discontinued PRISM4 Phase 3 trial for CP101 in recurrent C. difficile; database locked, no treatment-related SAEs.
Court adopted Finch's claim constructions for 7/8 terms in patent case vs Ferring/Rebiotix; jury trial set May 2024.
Repaid $16.2M debt to Hercules, subleased Hood Park facility, and launched Strain Bank for licensing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Finch Therapeutics Group, Inc. reported the fourth quarter of 2022 results: net income $27.0 million.

Period: the fourth quarter of 2022
Net income: $27.0 million
Result: reported results

Exact text from the filing

Finch reported a net loss of $27.0 million for the fourth quarter of 2022

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Finch Therapeutics Group, Inc. reported the full year of 2022 results: net income $114.6 million.

Period: the full year of 2022
Net income: $114.6 million
Result: reported results

Exact text from the filing

Finch reported a net loss of $114.6 million for the full year of 2022

View on SEC.gov

Browse all earnings releases →

Finch Therapeutics Group, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-009487

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.